GlaxoSmithKline drops filings of anti-emetic
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has withdrawn filings for its anti-emetic Rezonic/Zunrisa (casopitant), citing required further safety data that would have delayed product launch and thereby affected profitability. The drug was being developed for chemotherapy-induced and post-operative nausea and vomiting, and had been filed in the US, the EU and other countries.